Loading…
← CockpitCompetitor Analysis › 000908.SZ CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class AOpen in the cockpit ↗

CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A000908.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.

Momentum laggard 15
Mkt cap
$1.85B
US dollars, full cap
Free float
95%
of shares outstanding
$/day
$8.75M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-17.1 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥4.74
1D-1.5%
1W-9.0%
1M-14.1%
3M-32.6%
6M-37.8%
YTD-34.1%
1Y-35.0%
ATR %3.6%
52w lowhigh50.0% off high

What CSPC Hunan Jingfeng Pharmaceutical does

Changde-based drug maker, renamed under the CSPC group, selling branded heart, cancer, bone-joint and digestive injections and Chinese-medicine capsules.

Sells branded prescription injections and Chinese-medicine capsules mainly to hospitals, using a mix of distributor recruitment and its own sales team, with several products held exclusive nationally. A court-led restructuring finished in early 2026, and the company now carries the CSPC group name in its title and logo.

Products and services

  • Cardio-cerebral drugs (Xinnaoning capsules, tirofiban inject
  • Cancer injections (pemetrexed, gemcitabine, irinotecan)
  • Bone, joint and pain drugs (sodium hyaluronate injection)
  • Digestive injections (esomeprazole, omeprazole)
  • Women's and children's Chinese-medicine products
  • Anti-infective injections and sprays

Customers

  • Hospitals
  • Pharmaceutical distributors
  • Retail pharmacies (OTC)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Branded injections and Chinese-medicine…

What could go right

  • Fresh start after court-led debt restructuring
  • Exclusive products on the national reimbursement list

What could go wrong

  • Centralized procurement price cuts
  • Loss-making segment risk

Moat: narrow (regulatory licence, brand). Several nationally exclusive Chinese-medicine products on the national reimbursement list; now under the CSPC group name.

Headquarters: Changde, China · Employees: 463

Named competitors

CSPC Hunan Jingfeng Pharmaceutical at a glance

Size CSPC Hunan Jingfeng Pharmaceutical (000908.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.85B, the 1251st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥4.74 on 18 Nov 2026.

Performance Over six months the shares fell 37.8%, against -4.7% for the median peer and -20.0% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue grew 5.3% over the last twelve months (peer median +10.0%); the operating margin is -18.3% (peer median 15.0%).

Valuation It trades at 25.8× enterprise value to sales against a peer median of 3.5× (most expensive of 21).

Capital Return on invested capital runs 17.1 points below its cost of capital (5.0% WACC).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 97000908.SZ 61
Six months, rebased to 100: CSPC Hunan Jingfeng Pharmaceutical against the median of its 20 peers (local-currency closes).

CSPC Hunan Jingfeng Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥414MCN¥375MCN¥412MCN¥650MCN¥833M
Revenue growth—-9%-37%-22%—
Gross profitCN¥270MCN¥215MCN¥240MCN¥421MCN¥599M
EBITDAn/a-CN¥16.2MCN¥11.1M-CN¥56.9MCN¥42.8M
Net income-CN¥34.8M-CN¥80.9MCN¥152M-CN¥236M-CN¥123M
Free cash flow-CN¥159MCN¥54.8M-CN¥6.93MCN¥24.6MCN¥110M
Capital expenditureCN¥63.9MCN¥4.57MCN¥1.38MCN¥10.4MCN¥13.5M
Total debtCN¥6.73MCN¥286MCN¥466MCN¥601MCN¥608M

Quarterly statements and history in the cockpit →

CSPC Hunan Jingfeng Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-20%-10%0%+10%DMPCOHANCE600211300573300009PFIZER605507000028ZYMERAREALIVUS0023993933SHILPAMEDETON60066405124540AGIO000908.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. CSPC Hunan Jingfeng Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×10×20×DMPCOHANCE600211300573300009PFIZER605507000028ZYMEALIVUS3933SHILPAMEDETONAGIO000908.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. CSPC Hunan Jingfeng Pharmaceutical is the large dot.

CSPC Hunan Jingfeng Pharmaceutical competitors and peer comparison

Head to head with its named competitors (000908.SZ vs 600276.SS vs 600535.SS vs 002603.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginEV / SalesReq g
CSPC Hunan Jingfeng Pharmaceutical 000908.SZ$1.85B-38%+5%-18%25.8×n/a
Jiangsu Hengrui Pharmaceuticals 600276.SS$45.7B-13%+6%27%8.0×13.4%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%2.2×-7.5%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%2.9×-3.9%
Shandong Buchang Pharmaceuticals 603858.SS$2.25B-7%+4%10%1.5×-2.5%

How CSPC Hunan Jingfeng Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

CSPC Hunan Jingfeng Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure000908.SZPeer medianRank in peer set
1-month return-14.1%+0.7%3rd lowest of 21
6-month return-37.8%-4.7%lowest of 21
Distance from 52-week high-50.0%-28.3%4th lowest of 21
Revenue growth (TTM)+5.3%+10.0%9th lowest of 21
Operating margin-18.3%15.0%3rd lowest of 21
EV / Sales25.8×3.5×most expensive of 21
ROIC minus cost of capital-17.1 pp+2.4 pp3rd lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
CSPC Hunan Jingfeng Pharmaceutical 000908.SZChina$1.85B-38%+5%-18%25.8×n/an/a
Dermapharm DMP.DEGermany$1.85B-29%+2%21%2.3×-3.4%+8.0%
Cohance Lifesciences COHANCE.NSIndia$1.87B+7%+14%2%8.6×n/an/a
Tibet Rhodiola Pharmaceutical 600211.SSChina$1.87B-8%+13%27%3.4×-1.2%+16.7%
Shenyang Xingqi Pharmaceutical 300573.SZChina$1.83B-25%+17%33%4.2×5.4%+29.1%
Anhui Anke Biotechnology (Group) 300009.SZChina$1.88B-12%-9%30%4.8×8.0%+9.3%
Pfizer PFIZER.NSIndia$1.88B-20%+12%34%5.5×11.2%+2.4%
Guobang Pharma 605507.SSChina$1.82B-6%+3%12%1.9×-6.0%+7.4%
China National Accord Medicines 000028.SZChina$1.81B-3%0%2%0.3×-9.5%+4.2%
Zymeworks ZYMEUnited States$1.81B+5%+98%17%8.9×n/an/a
Ultragenyx Pharmaceutical RAREUnited States$1.81B-24%+16%-64%3.7×n/an/a
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%2.0×10.1%+5.0%
Alivus Life Sciences ALIVUS.NSIndia$1.90B+36%+8%31%6.3×20.1%+6.2%
Shenzhen Hepalink Pharmaceutical 002399.SZChina$1.80B-12%-6%8%2.1×-0.7%+0.5%
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%0.6×1.2%+7.8%
Shilpa Medicare SHILPAMED.NSIndia$1.91B+94%+37%21%10.1×n/an/a
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%12.4×21.9%+359.6%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%0.7×-5.3%+8.2%
Grand Pharmaceutical 0512.HKHong Kong$1.93B-25%+7%13%1.5×1.2%+14.1%
Tsumura & 4540.TJapan$1.93B+6%+13%18%2.0×n/an/a
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%8.3×n/an/a

Questions

Who are CSPC Hunan Jingfeng Pharmaceutical's main competitors?
Named competitors: Jiangsu Hengrui Pharma (600276.SS), Tasly Pharmaceutical (600535.SS), Yiling Pharmaceutical (002603.SZ), Buchang Pharma (603858.SS). The cockpit's measured peer set (industry) also includes Dermapharm (DMP.DE), Cohance Lifesciences (COHANCE.NS), Tibet Rhodiola Pharmaceutical (600211.SS), Shenyang Xingqi Pharmaceutical (300573.SZ), Anhui Anke Biotechnology (Group) (300009.SZ), Pfizer (PFIZER.NS).
Is CSPC Hunan Jingfeng Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 25.8× against a peer median of 3.5×, most expensive of 21 in its peer set.
How has CSPC Hunan Jingfeng Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -37.8% against -4.7% for the median peer; over one year -35.0%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.